Please be advised that Cytox Limited was placed into Liquidation on 4 January 2024, with Simon Farr and Anthony Collier of FRP Advisory Trading Limited being appointed Joint Liquidators of the Company. If you are owed money by Cytox Limited, or require further information about the Liquidation, please do not hesitate to contact email@example.com.
May 4, 2022
Research shows link between Alzheimer’s disease and lifestyle and wellbeing
A new study published in the Journal of the American Medical Association reveals that over a third of cases of Alzheimer’s disease are linked to 8 lifestyle and wellbeing factors that the authors describe as ‘modifiable’. They are midlife obesity, midlife hypertension, physical inactivity, depression, smoking, low education, diabetes, and hearing loss. This means that, although your genetic makeup is an important contributor to your risk of developing Alzheimer’s disease, other factors have a significant impact too. This could be described as the 60/40 rule – genetics account for 60% of your risk and lifestyle for 40%. So, as shown in the JAMA article, part of the risk is controllable.
The Alzheimer’s Risk Test, developed by Sampled Smart Labs, Piscataway, New Jersey powered by genoSCORE™ looks at your genes, or the code that was passed to you by your parents that determines your features and characteristics, to find out if you have been born with a higher or lower risk than other people your age. The personalized genetic assessment provided enables physicians and their patients to take proactive steps that could delay or prevent the onset of disease. Knowing an individual’s genetic risk will help them to assess the importance of taking action on other factors. Behaviour change is difficult, but making lifestyle changes that focus on brain health, specifically aimed at those 8 modifiable risk factors, offers the potential to reduce the chances of Alzheimer’s disease happening.
About Cytox (www.cytoxgroup.com)
Without new drug therapies, the economic and healthcare cost burden of dementia - including Alzheimer's disease (AD) - is estimated to exceed $1tn per year in the next decade2. AD – a highly complex disease with risk factors based in genetics, lifestyle, age, and environment. Cytox’s products technology genoSCORE™ and genoTOR™ use Polygenic Risk Scoring (PRS) to predict the risk of individuals developing AD, and to improve clinical trial outcomes through patient stratification and the genetic characterisation of the disease.
The genoSCORE technology underpins non-invasive, genetic tests to assess the risk of cognitive decline due to Alzheimer’s disease (AD). The test, which uses a simple blood or saliva sample, analyses over 100,000 single nucleotide polymorphisms (SNPs) - small genetic variations - that are associated with AD. As such, the test generates a patient-specific polygenic risk score (PRS).
Developers of new AD drug therapies can also test to identify and recruit patients to clinical studies, ensuring the selection of the most suitable candidates, those most likely to experience cognitive decline over the time period of the study.
About Alzheimer’s Risk Test
In the United States, Sampled Smart Labs, Piscataway, New Jersey have developed the Alzheimer’s Risk Test, powered by genoSCORE™
Clinicians can use the test to assess patients for the risk of developing Alzheimer's disease, before symptoms arise, prior to invasive cerebrospinal fluid (CSF) testing or expensive scanning techniques. Furthermore, the test’s simplicity of use would enable elderly and vulnerable patients self-isolating due to COVID-19, or not wishing or easily able to attend healthcare settings, to provide a suitable sample from home.